|
|
Interleukin-1β |
|
Vaxjo ID |
55 |
|
Vaccine Adjuvant Name |
Interleukin-1β |
|
Adjuvant VO ID |
VO_0001297
|
|
Stage of Development |
Research |
|
Components |
IL-10; IL-1; human Interleukin 1β mature polypeptide 117-259. This protein is composed of 12 anti-parallel b-strands folded into a six-stranded
barrel, with 3-fold symmetry about the axis of the barrel (Vogel and Powell, 1995). |
|
Preparation |
Primary adjuvant. Active by oral, intravenous, intraperitoneal and subcutaneous routes. It can be administered admixed with antigen or separately (Vogel and Powell, 1995). |
|
Function |
It increases both T-dependent and T-independent responses to different types of antigens. Active on both primary and secondary responses (Vogel and Powell, 1995). |
|
Safety |
IL-1 is a major inflammatory mediator; thus its use in vivo may have many unwanted effects. Phase I trials demonstrated severe hypotension as major side effect, as well as pain, respiratory and hermatological alterations. However, the immunostimulatory effects of IL-1 are evident at doses much lower than those yielding toxicity (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
